17-α-羟孕酮己酸酯预防有指征行宫颈环扎术史孕妇早产的有效性。
Effectiveness of 17-α-hydroxyprogesterone caproate on preterm birth prevention in women with history-indicated cerclage.
机构信息
Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania.
出版信息
Am J Perinatol. 2013 Oct;30(9):755-8. doi: 10.1055/s-0032-1332799. Epub 2013 Jan 22.
OBJECTIVE
To determine whether 17-α-hydroxyprogesterone caproate (17P) reduces the incidence of preterm birth in women with a history-indicated cerclage.
STUDY DESIGN
Retrospective cohort study of women who received a cerclage for a prior preterm birth, analyzed based on exposure to 17P. The primary outcome variable was delivery < 35 weeks. Secondary outcomes were preterm birth < 37, 32, 28, and 24 weeks; interval between cerclage placement and delivery; gestational age at delivery; and infant birth weight.
RESULTS
Fourteen women received 17P and 80 did not. Baseline characteristics did not differ between these two groups. Preterm delivery at < 35 weeks did not differ between those who received 17P and those who did not (29% versus 15%, p = 0.46). There were no significant differences between the groups for any other outcome.
CONCLUSION
17P does not appear to have an effect on preterm birth < 35 weeks in women with a history-indicated cerclage.
目的
确定 17-α-羟孕酮己酸酯（17P）是否降低有既往宫颈环扎指征的女性早产的发生率。
研究设计
对因先前早产而接受宫颈环扎的女性进行回顾性队列研究，根据是否接受 17P 进行分析。主要结局变量为分娩<35 周。次要结局包括早产<37、32、28 和 24 周；宫颈环扎放置与分娩之间的间隔；分娩时的胎龄；和婴儿出生体重。
结果
14 名女性接受了 17P，80 名女性没有。这两组之间的基线特征没有差异。接受 17P 和未接受 17P 的女性在<35 周的早产发生率没有差异（29%比 15%，p=0.46）。两组在任何其他结局上均无显著差异。
结论
在有既往宫颈环扎指征的女性中，17P 似乎对<35 周的早产没有影响。
Zotero 插件